DMX-200 for FSGS in people taking an ARB medicine
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial studies whether DMX-200 is safer and works better than placebo for people with FSGS who are already on (or can switch to) an ARB blood-pressure/kidney-protection medicine. It also looks at side effects over a long follow-up period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 12 to 80, or a teen under 18 with kidney function in the study’s allowed range.
- Your kidney disease is FSGS confirmed by a kidney biopsy within the last 7 years (not from another known cause).
- You take an ARB at the highest dose you can tolerate, or you are willing to switch to one.
- Your protein in the urine is high (or your 24-hour urine protein is high) based on screening tests.
- If you take certain kidney-related medicines (steroids or others like SGLT2 inhibitors), their dose must have been stable for the required time before screening.
- You must meet key safety labs/vitals (kidney filtration level, blood pressure range, and blood potassium/liver tests not too high).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SK-09 in healthy volunteers to see if it is safe and how the body processes it. The results will help decide the right dose for future studies.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This study tests a new medicine called BAY 3401016 to see if it can help adults with Alport syndrome, a genetic condition that affects the kidneys. The drug is given as an infusion or injection and the study will check how well it works and if it is safe.
This study tests an investigational drug (BI 764198) in adults and teens with different types of kidney disease. The goal is to see if the drug can help slow kidney damage. You may be able to join if your kidney function is at a certain level, you are on stable blood pressure medications, and you haven't had recent strong immune treatments.
Hear when a new FSGS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.